ArticleFrontiers in pharmacology2026
Can
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: 5-fluorouracil-based regimen FOLFOX (5-fluorouracil, folinic acid, oxaliplatin) is the first-line chemotherapeutic for metastatic colorectal cancer patients. On the other hand, the medicinal herb Methods: Human HCT-116 xenograft-bearing and murine Colon-26 orthotopic tumor-bearing mouse models were established and received FOLFOX and/or PV water extract treatments for 3 weeks. FOLFOX was administered intravenously once a week and PV water extract was administered daily by oral gavage except on the FOLFOX administration day. The levels of metabolising enzymes dihydropyrimidine dehydrogenase (for 5-fluorouracil), serine hydroxymethyltransferase (for folinic acid), as well as molecules, cysteine, methionine and reduced glutathione, involved in oxaliplatin biotransformation, were determined in plasma of xenograft-bearing mice receiving FOLFOX and/or PV water extract treatment. The tumor progression, metastasis and tumor microenvironment in mice were also assessed. Results: The PV water extract treatment did not affect the plasma levels of metabolising enzymes of 5-fluorouracil and folinic acid, nor the plasma levels of cysteine, methionine and reduced glutathione in HCT-116 xenograft-bearing mice. On the other hand, the combined treatment of FOLFOX and PV water extract inhibited both HCT-116 and Colon-26 tumor growth, with HCT-116 tumor weight of FOLFOX plus PV water extract group being the lowest among all treated groups. PV water extract treatment could further potentiate the anti-angiogenesis, apoptosis and immunomodulatory effect of FOLFOX in colon tumors. Conclusion: This is the first report to demonstrate that no observable interference induced by PV water extract on the plasma levels of selected metabolism enzymes and precursor molecules of FOLFOX component drugs in colon tumor-bearing mice. The combined use of FOLFOX plus PV water extract resulted in better anti-tumor efficacy in colon cancer mouse models than single treatment alone. The beneficial potentials of combined use of FOLFOX and PV water extract has been scientifically verified, which supports the clinical use in colon cancer management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.